Given the link between DNA methylation and immune pathways in MASLD progression, Pant et al. (2023) employed a DNA demethylating agent (a DNMT1 inhibitor) to treat MASLD mice fed a Western-style diet. The gene discussed is DNMT1; the disease is metabolic dysfunction-associated steatotic liver disease.